Two biotech stocks hit meaningful highs this summer because Josh Brown put them on a list. The list has a name. It's called Best Stocks. Not Good Stocks or Stocks We Think Might Work Out. Best Stocks.
Brown and Sean Russo broke down these two stocks. They used words and possibly charts. The stocks responded by going up, which proves that price action follows podcast appearances the way thunder follows lightning.
Meaningful highs. That's the phrase here. Not highs. Not new highs. Meaningful highs. The stocks didn't just go up. They went up with purpose. With intention. They sat down and had a conversation with themselves about what really matters before deciding to climb.
Retail traders are now panic-buying these names because a man with a list said they were the best. They're not buying because of phase three trial results or FDA timelines or even which disease the company is trying to cure. They're buying because the list exists and they were not consulted during its creation.
The biotech sector is perfect for this. Complicated science that nobody understands. Binary outcomes that wipe out accounts. Stocks that move 40% on a single headline about a molecule with nineteen syllables. But sure, the reason these two ripped is because they landed on a summer reading list.
Sean Russo broke them down. Russo. The man showed up to do his job and now his name is in a financial headline. He probably has a mortgage and a reasonable explanation for why these stocks matter. None of that made it into the summary.
Somewhere right now a day trader is watching this segment on mute with three monitors and a dream, about to risk his kid's college fund on biotech stocks because a list told him they were meaningful.
Photo by on Unsplash
Leave a Comment